Outcome of treatment of hyperthyroidism
Tóm tắt
This is a retrospective study designed to evaluate the initial response to carbimazole in patients with Graves’ disease (GD), possible determinants of that response, the frequency of occurrence of adverse effects during treatment with carbimazole and the frequency of transient and permanent hypothyroidism after treatment with 131I in patients with GD and multinodular goiter (MNG). Data were collected from patients who first presented with GD or MNG at the Department of Endocrinology of the Royal Infirmary of Edinburgh between 1 January 1993 and 31 August 1996. Patients were divided into three groups: patients with GD treated with a daily dose of 40 mg carbimazole, patients with GD treated with a single dose of 400 MBq 131I, and patients with MNG treated with the same dose of 131I. Of the patients younger than 30 years, 50% remained biochemically hyperthyroid after 4–6 weeks of treatment with carbimazole, compared to 14% of patients over 30. Other determinants of the response to carbimazole expressed as the fall in thyroid hormone levels after 4–6 weeks were: pretreatment levels of FT4, T3, TRAb and the 4 h 131I uptake, patients with the higher levels responding significantly better to carbimazole. Adverse effects were reported in 11.5% of patients. Of the patients with GD treated with 131I, 62.6% became hypothyroid, transient hypothyroidism occurred in only 2.4% of these cases. The main predictors of development of hypothyroidism were positive titres of antithyroid peroxidase antibodies (AbTPO) and antithyroglobulin antibodies (AbTg), with positive predictive values of 79.5 and 91.6 respectively. None of the patients with MNG became hypothyroid after treatment with 131I, a response significantly different from patients with GD. In conclusion, GD younger patients might benefit from higher initial doses of carbimazole. In patients with positive titres of AbTPO and AbTg, lower doses of 131I might prevent hypothyroidism. Transient hypothyroidism was underestimated in this study. No permanent thyroxin replacement therapy should be started within the first six months after 131I treatment. (J. Endocrinol. Invest. 22: 250–256, 1999)
Tài liệu tham khảo
De Groot L.J., Larsen P.R., Hennemann G. The thyroid and its diseases. Churchill Livingstone, Edinburg, 1996, 6th edition.
De Bruin T.W.A., Croon C.D.L., De Klerk J.M.H., Van Isselt J.W. Standardized radioiodine therapy in Graves’ disease: the persistent effect of thyroid weight and radioiodine uptake on outcome. J. Int. Med. 1994, 236: 507–513.
Feldt-Rasmussen U., Glinoer D., Orgiazzi J. Reassessment of antithyroid drug therapy of Graves’ disease. Annu. Rev. Med. 1993, 44: 323–334.
Franklyn J.A. The management of hyperthyroidism. New Engl. J. Med. 1994, 30: 1731–1738.
Farrar J.J., Toft A. Iodine-131 treatment of hyperthyroidism: current issues. Clin. Endocrinol. 1991, 35: 207–212.
Weetman A.P. How anti thyroid drugs work in Graves’ disease. Clin. Endocrinol. 1992, 37: 317–318.
Braverman L.E. Is there one succesful antithyroid regimen for Graves’ disease? Lancet 1996, 348: 697–698.
Jenkins R.M., Evans D.M.D. Carbimazole hypersensitivity and liver damage. Br. J. Clin. Practice 1981, 35 (11–12): 415–417.
Peters H., Fisher C., Bogner U., Reiners C., Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs calculated 131I iodine activity. Results from a prospective, randomized, multicenter study. Eur. J. Clin. Invest. 1995, 25: 186–193.
Sridama V., McCormick M., Kaplan E.L., Fauchet R., De Groot L.J. Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. New Engl. J. Med. 1984, 311 (7) 426–432.
Uy H.L., Reasner C.A., Samuels M.H. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves’ disease. Am. J. Med. 1995, 99: 173–179.
Toft A. Transient hypothyroidism. Clin. Endocr. 1997, 46: 7–8.
Peters H., Fisher C., Bogner U., Reiners C., Schleusener H. Reduction in thyroid volume after radioiodine therapy of Graves’ hyperthyroidism: results of a prospective, randomized, multicenter study. Eur. J. Clin. Invest. 1996, 26: 59–63.
Benker G., Vitti P., Kahaly G., Raue F., Tegler L., Hirche H., Reinwein D., the European Multicenter Study Group. Response to methimazole in Graves’ disease. Clin. Endocrinol. (Oxf.) 1995, 43: 257–263.
Yamada T., Aizawa T., Koizumi Y., Komiya I., Ichikawa K., Hashizume K. Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves’ disease. J. Am. Geri. Soc. 42 (5) 1994, 513–516.
Page S.R., Sheard C.E., Herbert M., Hopton M., Jeffcoate W.J. A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin. Endocrinol. (Oxf.) 1996, 45: 511–515.
Reinwein D., Benker G., Lazarus J.H., Alexander W.D., the European Multicenter Study Group on Antithyroid Drug Treatment. Prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. J. Clin. Endocrinol. Metab. 1993, 76: 1516–1521.
Aizawa Y., Yoshida K., Kaise N., Fukazawa H., Kiso Y., Sayama N., Hori H., Abe K. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves’ disease: prevalence, mechanism and prognosis. Clin. Endocrinol. (Oxf.) 1996, 46: 1–5.
Gomez N., Gomez J.M., Orti A., Gavalda L., Villabona C., Leyes P., Soler S. Transient hypothyroidism after iodine-131 therapy for Graves’ disease. J. Nucl. Med. 1995, 36: 1539–1542.
Lindsay R.S., Toft A.D. Hypothyroidism. Lancet 1997, 349: 413–417.
Franklyn J.A., Daykin J., Holder R., Sheppard M.C. Radioiodine therapy compared in patients with toxic nodular or Graves’ hyperthyroidism. Q. J. Med. 1995, 88: 175–180.
Berg G., Michanek A., Holmberg E., Nystrom E. Clinical outcome of radioiodine treatment of hyperthyroidism: a follow up study. J. Int. Med. 1996, 239: 165–171.
Sawers J.S.A., Toft A.D., Irvine W.J., Brown N.S., Seth J. Transient hypothyroidism after iodine-131 treatment of thyrotoxicosis. J. Clin. Endocrinol. Metab. 1980, 50: 226–229;.